Intestinal Cancer Blood Multi-Gene Methylation Combined Detection Kit (Chang Ai Ke®)

Multi-gene methylation detection test for colorectal cancer screening and risk assessment. Uses advanced liquid biopsy technology to identify epigenetic biomarkers associated with colorectal malignancy. Enables non-invasive early detection and personalized patient stratification for clinical decision-making.

A blood-based gene methylation detection kit for hepatocellular carcinoma with industry-leading performance metrics. This approved product is part of BioChain's comprehensive coverage of major digestive system cancers.

The world's first approved gene methylation early detection product for esophageal cancer, representing a breakthrough in early cancer diagnosis. This product has received NMPA certification and is part of BioChain's comprehensive digestive system cancer screening portfolio.

A home-based colorectal cancer early screening product that detects multi-gene mutations combined with DNA methylation in fecal exfoliated cells from the intestinal tract. It features 6 target genes and over 30 mutation sites, enabling non-invasive and painless screening that can identify colorectal cancer risk 5-7 years in advance. The test can be performed at home without hospital visits.

A combined fecal occult blood and fecal DNA genetic testing kit for cancer early screening. This diagnostic product detects multiple biomarkers including occult blood and genetic markers in stool samples to assess colorectal cancer risk.

Gene methylation-based diagnostic test for early detection of hepatocellular carcinoma with industry-leading performance metrics. This blood-based test enables non-invasive screening for liver cancer risk stratification. The product is approved by NMPA and integrated into multiple hospital and insurance systems.

A comprehensive blood-based screening service designed to detect multiple cancer types simultaneously through gene methylation analysis. This service utilizes advanced NGS technology and is available as a clinical testing service.

A blood-based gene methylation early detection product for colorectal cancer that was the first in China to receive NMPA approval and is marketed under the brand name Siboding®. The product has received authorizations from the FDA, NMPA, and EU CE, representing the world's earliest simultaneous approval from all three major regulatory bodies.

Multi-tumor marker detection kit utilizing protein chip technology with chemiluminescence for simultaneous identification of multiple cancer biomarkers in blood and serum samples. Designed for clinical diagnosis and monitoring of various malignancies, this in vitro diagnostic test enables rapid quantitative analysis to support oncology patient management and treatment decisions.

A diagnostic test product for digestive tract screening designed to detect hidden blood in the gastrointestinal system. It is used as part of early cancer screening protocols to identify potential gastrointestinal health issues.

A targeted blood-based early detection service for specific cancer types utilizing gene methylation biomarkers. This clinical testing service is performed by BioChain's certified medical laboratory.

In-vitro diagnostic test for detecting tumor markers and cancer-related antigens in blood and other biological samples. The test aids in cancer screening, diagnosis, and treatment monitoring.